Double‐Blind Placebo Challenge Confirmation of Diphenhydramine Allergy
ABSTRACT Diphenhydramine, a first‐generation H1–antihistamine commonly used for allergic symptom relief and infusion premedication, rarely causes true systemic hypersensitivity. When suspected reactions are mild and subjective—particularly in anxious patients—objective confirmation is essential.
Ruchi Patel +2 more
wiley +1 more source
Successful treatment of chronic spontaneous urticaria and bladder pain syndrome with montelukast and/or omalizumab: a case report. [PDF]
Bulut G.
europepmc +1 more source
This Mendelian randomization study investigated causal relationships between 15 micronutrients, 91 inflammatory proteins, and 13 inflammatory skin diseases. Genetically predicted higher Vitamin B6 levels showed a significant causal association with increased risk of hidradenitis suppurativa (FDR < 0.05).
Shengliang Gu +4 more
wiley +1 more source
Rebound Pruritus and Urticaria Post-discontinuation of Chronic Cetirizine Use: A Case Report. [PDF]
Seng JJB, Cai M, Oka P.
europepmc +1 more source
Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska +8 more
wiley +1 more source
A constant rate of DNA damage that is not perfectly repaired will cause a constant rate of DNA mutations. The chance of mutation will increase if DNA is prone to damage, such as occurs in somatic hypermutation (SHM) hotspots and GC‐rich DNA. Thus, if one mutation‐prone DNA site drives disease, the age of onset of disease and degree of penetrance should
Piet C. de Groen
wiley +1 more source
Comment on "The relationship of FricTest® responses with an urticaria activity score, urticaria control test and quality of life scales in patients with symptomatic dermographism". [PDF]
Satapathy P, Mehta R, Sah R.
europepmc +1 more source
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba +11 more
wiley +1 more source
Does clinical exposure to different skin tones during training improve diagnostic ability?
Abstract Background Previous studies have shown that medical students demonstrate poorer performance when diagnosing pathology in skin of colour (SOC) compared to white skin (WS); it is important to understand the reasons underpinning this. If not addressed, poorer differential diagnostic ability in certain skin tones could entrench existing racial ...
Yusra Shammoon +10 more
wiley +1 more source
BRIDGE implementation science study to improve chronic spontaneous urticaria outcomes in Italy. [PDF]
Asero R +7 more
europepmc +1 more source

